This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Paul A. Cullis, MD
Department of Neurology 6E University Health Center 4201 St Antoine Detroit, MI 48201

Arch Neurol. 1984;41(2):137.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—In their article "Myelopathy After Herpes Zoster" (ARCHIVES 1983;40:445-446), Muder et al described a patient with herpes zoster myelitis who was treated relatively unsuccessfully with vidarabine. This finding contradicts two previous reports of successful treatment with vidarabine.^1,2

It is interesting to note that the authors' patient continued to receive prednisone during vidarabine therapy, whereas our patient's methylprednisolone therapy was discontinued before initiation of treatment with vidarabine.¹ The patient of Corston et al,² who also did well, was apparently never treated with steroids.

One might conclude from these limited data that steroids should not be administered to patients with herpes zoster myelitis. The known immunosuppressive effects of steroids may facilitate replication of the virus and vitiate the effectiveness of vidarabine therapy by decreasing production of native interferon, with which vidarabine has been shown to have a synergistic effect. The available evidence from the three reported . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?